Frontlight ResearchEarly access
CompletedNo phase
Perioperative Salivary Alpha-amylase as a Predictor of Delirium After Lower Extremity Vascular Bypass Surgery
Key facts
- Who runs it
- Tanta University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 10 Feb 2024
- Ended
- 19 Jun 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Salivary Alpha-amylase
- Record updated
- 25 June 2025
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age ≥ 65 years
- Both sexes
- American Society of Anesthesiologists (ASA) physical status III
- Undergoing lower extremity vascular surgery under general anesthesia
Who cannot take part
- Patients who used any medication that could affect salivary glands (such as antihypertensive, antidepressants or antipsychotic drugs)
- History of psychiatric diseases or previous stroke
- Previous history of pod
- Inability to communicate
- Those with smoking and drinking habits
- Pregnant female
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to evaluate the role of salivary Alpha-amylase as a predictor biomarker of POD in elderly patients undergoing limb bypass surgery.
The 2 groups in the trial
- Postoperative delirium (POD) group
Patients who will develop postoperative delirium
Treatment: Salivary Alpha-amylase
- No Postoperative delirium (POD) group
Patients who will not develop postoperative delirium
Treatment: Salivary Alpha-amylase
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 25 June 2025